These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 15714080

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
    Pastores GM, Barnett NL, Kolodny EH.
    Clin Ther; 2005 Aug; 27(8):1215-27. PubMed ID: 16199246
    [Abstract] [Full Text] [Related]

  • 3. Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.
    Giuffrida G, Lombardo R, Di Francesco E, Parrinello L, Di Raimondo F, Fiumara A.
    J Med Case Rep; 2016 Nov 08; 10(1):315. PubMed ID: 27821156
    [Abstract] [Full Text] [Related]

  • 4. Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme.
    Hollak CE, Hughes D, van Schaik IN, Schwierin B, Bembi B.
    Pharmacoepidemiol Drug Saf; 2009 Sep 08; 18(9):770-7. PubMed ID: 19507165
    [Abstract] [Full Text] [Related]

  • 5. Substrate reduction therapy with miglustat for type 1 Gaucher disease: a retrospective analysis from a single institution.
    Machaczka M, Hast R, Dahlman I, Lerner R, Klimkowska M, Engvall M, Hägglund H.
    Ups J Med Sci; 2012 Mar 08; 117(1):28-34. PubMed ID: 22247978
    [Abstract] [Full Text] [Related]

  • 6. Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project.
    Giraldo P, Alfonso P, Atutxa K, Fernández-Galán MA, Barez A, Franco R, Alonso D, Martin A, Latre P, Pocovi M.
    Haematologica; 2009 Dec 08; 94(12):1771-5. PubMed ID: 19608672
    [Abstract] [Full Text] [Related]

  • 7. Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series.
    Serratrice C, Swiader L, Serratrice J.
    J Med Case Rep; 2015 Jun 23; 9():146. PubMed ID: 26100396
    [Abstract] [Full Text] [Related]

  • 8. Results from a 9-year Intensive Safety Surveillance Scheme (IS(3) ) in miglustat (Zavesca(®) )-treated patients.
    Brand M, Muller A, Alsop J, van Schaik IN, Bembi B, Hughes D.
    Pharmacoepidemiol Drug Saf; 2015 Mar 23; 24(3):329-33. PubMed ID: 25656910
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study.
    Cox TM, Amato D, Hollak CE, Luzy C, Silkey M, Giorgino R, Steiner RD, Miglustat Maintenance Study Group.
    Orphanet J Rare Dis; 2012 Dec 27; 7():102. PubMed ID: 23270487
    [Abstract] [Full Text] [Related]

  • 10. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.
    Pastores GM, Elstein D, Hrebícek M, Zimran A.
    Clin Ther; 2007 Aug 27; 29(8):1645-54. PubMed ID: 17919546
    [Abstract] [Full Text] [Related]

  • 11. Patients with Gaucher type 1: Switching from imiglucerase to miglustat therapy.
    Canda E, Kose M, Kagnici M, Ucar SK, Sozmen EY, Coker M.
    Blood Cells Mol Dis; 2018 Feb 27; 68():180-184. PubMed ID: 28111116
    [No Abstract] [Full Text] [Related]

  • 12. Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports.
    Amato D, Patterson MA.
    J Med Case Rep; 2018 Jan 27; 12(1):19. PubMed ID: 29373994
    [Abstract] [Full Text] [Related]

  • 13. Substrate reduction therapy.
    Platt FM, Jeyakumar M.
    Acta Paediatr; 2008 Apr 27; 97(457):88-93. PubMed ID: 18339196
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients.
    Smid BE, Ferraz MJ, Verhoek M, Mirzaian M, Wisse P, Overkleeft HS, Hollak CE, Aerts JM.
    Orphanet J Rare Dis; 2016 Mar 24; 11():28. PubMed ID: 27008851
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Miglustat: substrate reduction therapy for glycosphingolipid lysosomal storage disorders.
    Lachmann RH.
    Drugs Today (Barc); 2006 Jan 24; 42(1):29-38. PubMed ID: 16511609
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.